sintilimab,anlotinib
sino biopharmaceuticals,advenchen,eli lilly
['sclc', 'sintilimab', 'anlotinib']
#asco22 dr. discusses recurrent #sclc including abstract #8516 by dr. shuxiang ma of sintilimab (pd1) plus anlotinib. rr 49%, dcr 80%, mpfs 6m, mos 16m. is #vegf inhibition important for io here? note 43% never smokers. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him